Blood Pressure Targets in CKD

Lessons Learned from SPRINT and Previous Observational Studies

Elvira O. Gosmanova, Csaba Kovesdy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hypertension management is one of the most common clinical tasks in the care of patients with chronic kidney disease (CKD). Elevated blood pressure (BP) is associated with greater risk of all-cause mortality, cardiovascular (CV) disease, and CKD progression in this population. However, it is still debated, to what target(s) BP should be lowered in patients with signs of kidney damage. The Systolic Blood Pressure Intervention Trial (SPRINT) provided new and important information about the effects of lowering systolic BP to a target of <120 mmHg, which is lower than the levels currently recommended by the most guidelines (<140/90 mmHg). The SPRINT results were not only exciting but also surprising for many clinicians because evidence from well-conducted observational studies in CKD patient showed increased mortality in patients with CKD whose office systolic BP levels were <120 mmHg, as compared with systolic BP in 120–139 mmHg range. In the present review, we will discuss whether a systolic BP goal of <120 mmHg that was found to be beneficial for CV and all-cause mortality outcomes in the SPRINT can be generalized to the entire CKD population.

Original languageEnglish (US)
Article number88
JournalCurrent Cardiology Reports
Volume18
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Chronic Renal Insufficiency
Observational Studies
Blood Pressure
Mortality
Population
Disease Progression
Patient Care
Cardiovascular Diseases

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Blood Pressure Targets in CKD : Lessons Learned from SPRINT and Previous Observational Studies. / Gosmanova, Elvira O.; Kovesdy, Csaba.

In: Current Cardiology Reports, Vol. 18, No. 9, 88, 01.09.2016.

Research output: Contribution to journalReview article

@article{42767a6b2f184b5e9f3428b38bb1ed97,
title = "Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies",
abstract = "Hypertension management is one of the most common clinical tasks in the care of patients with chronic kidney disease (CKD). Elevated blood pressure (BP) is associated with greater risk of all-cause mortality, cardiovascular (CV) disease, and CKD progression in this population. However, it is still debated, to what target(s) BP should be lowered in patients with signs of kidney damage. The Systolic Blood Pressure Intervention Trial (SPRINT) provided new and important information about the effects of lowering systolic BP to a target of <120 mmHg, which is lower than the levels currently recommended by the most guidelines (<140/90 mmHg). The SPRINT results were not only exciting but also surprising for many clinicians because evidence from well-conducted observational studies in CKD patient showed increased mortality in patients with CKD whose office systolic BP levels were <120 mmHg, as compared with systolic BP in 120–139 mmHg range. In the present review, we will discuss whether a systolic BP goal of <120 mmHg that was found to be beneficial for CV and all-cause mortality outcomes in the SPRINT can be generalized to the entire CKD population.",
author = "Gosmanova, {Elvira O.} and Csaba Kovesdy",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s11886-016-0769-y",
language = "English (US)",
volume = "18",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "9",

}

TY - JOUR

T1 - Blood Pressure Targets in CKD

T2 - Lessons Learned from SPRINT and Previous Observational Studies

AU - Gosmanova, Elvira O.

AU - Kovesdy, Csaba

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Hypertension management is one of the most common clinical tasks in the care of patients with chronic kidney disease (CKD). Elevated blood pressure (BP) is associated with greater risk of all-cause mortality, cardiovascular (CV) disease, and CKD progression in this population. However, it is still debated, to what target(s) BP should be lowered in patients with signs of kidney damage. The Systolic Blood Pressure Intervention Trial (SPRINT) provided new and important information about the effects of lowering systolic BP to a target of <120 mmHg, which is lower than the levels currently recommended by the most guidelines (<140/90 mmHg). The SPRINT results were not only exciting but also surprising for many clinicians because evidence from well-conducted observational studies in CKD patient showed increased mortality in patients with CKD whose office systolic BP levels were <120 mmHg, as compared with systolic BP in 120–139 mmHg range. In the present review, we will discuss whether a systolic BP goal of <120 mmHg that was found to be beneficial for CV and all-cause mortality outcomes in the SPRINT can be generalized to the entire CKD population.

AB - Hypertension management is one of the most common clinical tasks in the care of patients with chronic kidney disease (CKD). Elevated blood pressure (BP) is associated with greater risk of all-cause mortality, cardiovascular (CV) disease, and CKD progression in this population. However, it is still debated, to what target(s) BP should be lowered in patients with signs of kidney damage. The Systolic Blood Pressure Intervention Trial (SPRINT) provided new and important information about the effects of lowering systolic BP to a target of <120 mmHg, which is lower than the levels currently recommended by the most guidelines (<140/90 mmHg). The SPRINT results were not only exciting but also surprising for many clinicians because evidence from well-conducted observational studies in CKD patient showed increased mortality in patients with CKD whose office systolic BP levels were <120 mmHg, as compared with systolic BP in 120–139 mmHg range. In the present review, we will discuss whether a systolic BP goal of <120 mmHg that was found to be beneficial for CV and all-cause mortality outcomes in the SPRINT can be generalized to the entire CKD population.

UR - http://www.scopus.com/inward/record.url?scp=84979224042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979224042&partnerID=8YFLogxK

U2 - 10.1007/s11886-016-0769-y

DO - 10.1007/s11886-016-0769-y

M3 - Review article

VL - 18

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 9

M1 - 88

ER -